We are pleased to announce that Janis Picurro has accepted the position of Principal Consultant in the Regulatory Practice at Lachman Consultants, effective December 18, 2017.

Ms. Picurro is a senior level regulatory professional with over 24 years of experience in the pharmaceutical industry where she had a career of progressively increasing responsibilities in Regulatory Affairs. Ms. Picurro has a broad working knowledge of regulatory requirements for generic drugs from development to approval and has extensive experience in ANDA, IND, NDA, and DMFs.

Prior to joining Lachman Consultants, Ms. Picurro served as Executive Director, Regulatory Affairs at Par Pharmaceutical and was responsible for the oversight and regulatory strategies associated with ANDA, NDA, IND and DMF filings (prior positions at Par include Director, Regulatory Affairs; and Manager, Regulatory Affairs R&D). Prior to joining Par, Ms. Picurro was Senior Director, Regulatory Affairs at Glatt Air Techniques’ Pharmaceutical Services Division and provided strategic guidance for both U.S. and German divisions. Prior positions held in her career include Manager, Regulatory Affairs and/or Senior Regulatory Associate at Able Laboratories, Bradley Pharmaceuticals, Alpharma, and Biocraft Laboratories.

Ms. Picurro earned her B.A. in Political Science from St. Peter’s College in New Jersey.

We welcome Janis to Lachman Consultants and wish her a long and successful career with our firm.

For nearly four decades, Lachman Consultants has been the leader in providing cost-effective consultation and remediation services to the worldwide pharmaceutical, biotechnology, biologic, medical device, diagnostic and dietary supplement industries. With its strong and extensive cadre of consultant specialists and an unparalleled management team, its Compliance, Science & Technology, and Regulatory Practices provide the most expert counsel and array of services available. Lachman Consultants is proud of its tradition of supporting industry efforts to develop and ensure safe, effective and high-quality medical products. It remains committed to helping the industry anticipate and address its challenges through the development and implementation of practical, sustainable and cost-effective solutions based on the integration of scientific principles, evolving regulatory expectations, and technology.